Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

Robert J. Motzer; Thomas E. Hutson; Piotr Tomczak; M. Dror Michaelson; Ronald M. Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Négrier; Cezary Szczylik; Sindy T. Kim; Isan Chen; Paul Bycott; Charles M. Baum; Robert A. Figlin

doi:10.1056/nejmoa065044

Abstract

Progression-free survival was longer and response rates were higher in patients with metastatic renal-cell cancer who received sunitinib than in those receiving interferon alfa (ClinicalTrials.gov numbers, NCT00098657 and NCT00083889 [ClinicalTrials.gov]).

Keywords

MedicineSunitinibRenal cell carcinomaInterferon alfaInternal medicineSunitinib malateHazard ratioGastroenterologyClinical endpointAlpha interferonOncologyConfidence intervalUrologyRandomized controlled trialInterferonCancerImmunologyImmunotherapy

Affiliated Institutions

Related Publications

Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer

Robert C. Flanigan , Sydney E. Salmon , Brent A. Blumenstein +6 more

Nephrectomy followed by interferon therapy results in longer survival among patients with metastatic renal-cell cancer than does interferon therapy alone.

2001 New England Journal of Medicine 1719 citations

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini , Elizabeth R. Plimack , V.P. Stus +24 more

Among patients with previously untreated advanced renal-cell carcinoma, treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progress...

2019 New England Journal of Medicine 3200 citations

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Robert J. Motzer , Konstantin Penkov , John B.A.G. Haanen +25 more

Progression-free survival was significantly longer with avelumab plus axitinib than with sunitinib among patients who received these agents as first-line treatment for advanced ...

2019 New England Journal of Medicine 2439 citations

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert J. Motzer , B. Yа. Alekseev , Sun Young Rha +35 more

Lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and overall survival than sunitinib. (Funded by Eisai and Merck Sharp and Dohme;...

2021 New England Journal of Medicine 1597 citations

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Ian D. Davis , Andrew Martin , Martin R. Stockler +29 more

Enzalutamide was associated with significantly longer progression-free and overall survival than standard care in men with metastatic, hormone-sensitive prostate cancer receivin...

2019 New England Journal of Medicine 1481 citations

Publication Info

Year: 2007
Type: article
Volume: 356
Issue: 2
Pages: 115-124
Citations: 5691
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

5691

OpenAlex

Cite This

APA Style

                            
                                
                                    Robert J. Motzer, 
                                
                                    Thomas E. Hutson, 
                                
                                    Piotr Tomczak
                                
                                et al.
                            
                            (2007). 
                            Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. 
                            New England Journal of Medicine
                            , 356
                            (2)
                            , 115-124.
                            https://doi.org/10.1056/nejmoa065044
                        

Identifiers

DOI: 10.1056/nejmoa065044